Zogenix Files Registration Statement for Proposed Follow-On Offering
SAN DIEGO, Aug 24, 2011 (GlobeNewswire via COMTEX) --
Zogenix, Inc. (Nasdaq:ZGNX) announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 12,000,000 shares of its common stock, or up to 13,800,000 shares if the underwriters exercise in full their option to purchase additional shares. All shares of the common stock to be sold in the offering will be offered by Zogenix.
Leerink Swann LLC and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering, and Stifel Nicolaus & Company, Incorporated, William Blair & Company, L.L.C. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. This offering will be made only by means of a prospectus. Once available, copies of the prospectus relating to this offering may be obtained from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Massachusetts 02110, or by calling toll-free 800-808-7525 or emailing a request to Syndicate@Leerink.com and from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152, or by calling toll-free 800-326-5897 or emailing a request to firstname.lastname@example.org.
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state or jurisdiction.
Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL(R) DosePro(R) (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead product candidate, Zohydro(TM) (hydrocodone bitartrate), is a novel, oral, single-entity (without acetaminophen) extended-release capsule formulation currently in Phase 3 clinical trials for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix's second DosePro product candidate, Relday(TM), is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia.
This news release was distributed by GlobeNewswire, www.globenewswire.com.
Zack Kubow | The Ruth Group
646.536.7020 | email@example.com
Victoria Aguiar | The Ruth Group